These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 19647176)
1. Biokinetic and dosimetric studies of 188Re-hyaluronic acid: a new radiopharmaceutical for treatment of hepatocellular carcinoma. Meléndez-Alafort L; Nadali A; Zangoni E; Banzato A; Rondina M; Rosato A; Mazzi U Nucl Med Biol; 2009 Aug; 36(6):693-701. PubMed ID: 19647176 [TBL] [Abstract][Full Text] [Related]
2. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. Lambert B; Bacher K; Defreyne L; Gemmel F; Van Vlierberghe H; Jeong JM; Dierckx RA; Van de Wiele C; Thierens H; De Vos F J Nucl Med; 2005 Jan; 46(1):60-6. PubMed ID: 15632035 [TBL] [Abstract][Full Text] [Related]
3. Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors. Müller C; Schubiger PA; Schibli R Nucl Med Biol; 2007 Aug; 34(6):595-601. PubMed ID: 17707798 [TBL] [Abstract][Full Text] [Related]
4. Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7-14)NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies. Smith CJ; Sieckman GL; Owen NK; Hayes DL; Mazuru DG; Volkert WA; Hoffman TJ Anticancer Res; 2003; 23(1A):63-70. PubMed ID: 12680195 [TBL] [Abstract][Full Text] [Related]
5. Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma. De Ruyck K; Lambert B; Bacher K; Gemmel F; De Vos F; Vral A; de Ridder L; Dierckx RA; Thierens H J Nucl Med; 2004 Apr; 45(4):612-8. PubMed ID: 15073257 [TBL] [Abstract][Full Text] [Related]
6. Preparation of cyclotron-produced 186Re and comparison with reactor-produced 186Re and generator-produced 188Re for the labeling of bombesin. Moustapha ME; Ehrhardt GJ; Smith CJ; Szajek LP; Eckelman WC; Jurisson SS Nucl Med Biol; 2006 Jan; 33(1):81-9. PubMed ID: 16459262 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Coradini D; Zorzet S; Rossin R; Scarlata I; Pellizzaro C; Turrin C; Bello M; Cantoni S; Speranza A; Sava G; Mazzi U; Perbellini A Clin Cancer Res; 2004 Jul; 10(14):4822-30. PubMed ID: 15269158 [TBL] [Abstract][Full Text] [Related]
8. Preparation and biodistribution of rhenium-188 ECD/Lipiodol in rats following hepatic arterial injection. Luo TY; Hsieh BT; Wang SJ; Lin WY; Lee TW; Shen LH; Su MJ Nucl Med Biol; 2004 Jul; 31(5):671-7. PubMed ID: 15219287 [TBL] [Abstract][Full Text] [Related]
10. Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas. Torres LA; Coca MA; Batista JF; Casaco A; Lopez G; García I; Perera A; Peña Y; Hernández A; Sanchez Y; Romero S; Leyva R; Prats A; Fernandez R Nucl Med Commun; 2008 Jan; 29(1):66-75. PubMed ID: 18049099 [TBL] [Abstract][Full Text] [Related]
11. Rhenium-188 based radiopharmaceuticals for treatment of liver tumours. Lambert B; Bacher K; Defreyne L Q J Nucl Med Mol Imaging; 2009 Jun; 53(3):305-10. PubMed ID: 19521309 [TBL] [Abstract][Full Text] [Related]
12. 186Re-liposome labeling using 186Re-SNS/S complexes: in vitro stability, imaging, and biodistribution in rats. Bao A; Goins B; Klipper R; Negrete G; Phillips WT J Nucl Med; 2003 Dec; 44(12):1992-9. PubMed ID: 14660726 [TBL] [Abstract][Full Text] [Related]
13. [Radiotherapy with (186)Re-lipiodol II for primary liver cancer patients]. Shi L; Zhang Z; Zhuang D; Cheng H; Gao Y; Wu M Zhonghua Wai Ke Za Zhi; 2002 Nov; 40(11):814-6. PubMed ID: 12487852 [TBL] [Abstract][Full Text] [Related]
14. Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment. Knapp FF; Beets AL; Guhlke S; Zamora PO; Bender H; Palmedo H; Biersack HJ Anticancer Res; 1997; 17(3B):1783-95. PubMed ID: 9179235 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and dosimetry of 188 Re-pharmaceuticals. Ferro-Flores G; Arteaga de Murphy C Adv Drug Deliv Rev; 2008 Sep; 60(12):1389-401. PubMed ID: 18547675 [TBL] [Abstract][Full Text] [Related]
16. Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study. Bernal P; Raoul JL; Vidmar G; Sereegotov E; Sundram FX; Kumar A; Jeong JM; Pusuwan P; Divgi C; Zanzonico P; Stare J; Buscombe J; Minh CT; Saw MM; Chen S; Ogbac R; Padhy AK Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1448-55. PubMed ID: 17692473 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of a 188Re-labeled alpha-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models. Miao Y; Owen NK; Fisher DR; Hoffman TJ; Quinn TP J Nucl Med; 2005 Jan; 46(1):121-9. PubMed ID: 15632042 [TBL] [Abstract][Full Text] [Related]
18. Lipiodol solution of 188Re-HDD as a new therapeutic agent for transhepatic arterial embolization in liver cancer: preclinical study in a rabbit liver cancer model. Paeng JC; Jeong JM; Yoon CJ; Lee YS; Suh YG; Chung JW; Park JH; Chung JK; Son M; Lee MC J Nucl Med; 2003 Dec; 44(12):2033-8. PubMed ID: 14660730 [TBL] [Abstract][Full Text] [Related]
19. Management of postsurgical recurrence of hepatocellular carcinoma with rhenium 188-HDD labeled iodized oil. Kumar A; Srivastava DN; Bal C J Vasc Interv Radiol; 2006 Jan; 17(1):157-61. PubMed ID: 16415146 [TBL] [Abstract][Full Text] [Related]